Waverly Advisors LLC Has $4.69 Million Stock Position in McKesson Corporation $MCK

Waverly Advisors LLC lifted its stake in shares of McKesson Corporation (NYSE:MCK) by 26.3% during the second quarter, Holdings Channel.com reports. The firm owned 6,208 shares of the company’s stock after acquiring an additional 1,294 shares during the period. Waverly Advisors LLC’s holdings in McKesson were worth $4,691,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Meiji Yasuda Asset Management Co Ltd. increased its position in McKesson by 0.5% in the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,262 shares of the company’s stock valued at $1,855,000 after buying an additional 11 shares in the last quarter. Investment Research Partners LLC grew its stake in McKesson by 0.7% in the fourth quarter. Investment Research Partners LLC now owns 1,624 shares of the company’s stock valued at $1,332,000 after acquiring an additional 11 shares during the period. IHT Wealth Management LLC increased its holdings in shares of McKesson by 0.9% during the fourth quarter. IHT Wealth Management LLC now owns 1,196 shares of the company’s stock valued at $981,000 after acquiring an additional 11 shares in the last quarter. Macroview Investment Management LLC raised its position in shares of McKesson by 3.9% during the fourth quarter. Macroview Investment Management LLC now owns 322 shares of the company’s stock worth $264,000 after purchasing an additional 12 shares during the period. Finally, Anchyra Partners LLC raised its position in shares of McKesson by 1.0% during the first quarter. Anchyra Partners LLC now owns 1,174 shares of the company’s stock worth $1,016,000 after purchasing an additional 12 shares during the period. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson Trading Down 1.2%

Shares of McKesson stock opened at $881.22 on Friday. The company has a market capitalization of $102.74 billion, a P/E ratio of 23.58, a price-to-earnings-growth ratio of 1.77 and a beta of 0.30. The stock has a fifty day simple moving average of $858.30 and a 200 day simple moving average of $840.99. McKesson Corporation has a 12-month low of $687.68 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating the consensus estimate of $9.56 by $0.37. The business had revenue of $105.38 billion for the quarter, compared to analysts’ expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business’s revenue was up 7.7% on a year-over-year basis. During the same period last year, the business earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, analysts predict that McKesson Corporation will post 44.65 EPS for the current year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, September 1st. This is an increase from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s payout ratio is 10.06%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. UBS Group upped their price objective on shares of McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup raised their price objective on shares of McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Wells Fargo & Company boosted their target price on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Finally, Royal Bank Of Canada assumed coverage on shares of McKesson in a research report on Wednesday, August 19th. They set a “sector perform” rating and a $845.00 target price for the company. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, McKesson currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.44.

Insider Buying and Selling

In related news, CEO Brian Tyler sold 8,463 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the transaction, the chief executive officer directly owned 5,919 shares in the company, valued at approximately $4,697,081.64. The trade was a 58.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO B Jr sold 111 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the sale, the chief accounting officer directly owned 521 shares of the company’s stock, valued at $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 17,338 shares of company stock worth $13,643,366. 0.06% of the stock is owned by insiders.

About McKesson

McKesson Corporation is a healthcare services and distribution company that supplies pharmaceuticals, specialty drugs, medical products and related services to pharmacies, hospitals, health systems, physicians and other healthcare providers. Its operations support the movement of prescription medicines and medical-surgical supplies from manufacturers to healthcare organizations and patients.

The company’s businesses include pharmaceutical distribution, specialty pharmaceutical services, medical-surgical supply distribution and technology solutions for pharmacies and other healthcare providers.